BackSCIENCE_HEALTH
Roche launches subcutaneous Tecentriq for lung cancer, cuts administration time to seven minutes
Roche announced Tecentriq SC, the first subcutaneous immunotherapy for lung cancer, reducing administration time to about seven minutes from hours of IV infusions. The rollout includes patient-support programs to offset high costs, with Western markets already adopting the formulation and India launching the product. The article notes eligibility constraints, PD-L1 marker relevance, and potential cost reductions as demand grows.
Why It Matters
This development could improve patient experience by shortening treatment time and enabling administration closer to home, while patient-support programs aim to widen access amid high upfront costs. However, affordability and eligibility remain key considerations for broader adoption.
Timeline
2 Events
Roche launches Tecentriq SC in India, reducing administration time to seven minutes
May 14, 2026
Roche announces the launch of Tecentriq SC for lung cancer, marking the first subcutaneous immunotherapy administration in this context and reducing delivery time to about seven minutes from hours-long intravenous infusions. The company highlights patient support programmes (Blue Tree, CGHS inclusion, EMI options) to lower treatment costs. The typical regimen may involve about six vials, with a maximum price around ₹3.7 lakh per vial at MRP, though costs can vary with treatment duration and patient response. Not all lung cancer patients are eligible (approximately 50% could be fit for therapy), and those with the PD-L1 marker have shown good results. The article also notes that price levels may decline over time as demand grows and access expands.
Western markets already offer Tecentriq SC
April 2026
The article notes that in Western markets, the subcutaneous version of Tecentriq has already been available for the past few months, indicating an earlier regional rollout before the India launch.